Behzad Aghazadeh - Net Worth and Insider Trading
Behzad Aghazadeh Net Worth
The estimated net worth of Behzad Aghazadeh is at least $1.4 Billion dollars as of 2023-09-24. Behzad Aghazadeh is the See Remarks of Immunomedics Inc and owns about 16,064,461 shares of Immunomedics Inc (IMMU) stock worth over $1.4 Billion. Details can be seen in Behzad Aghazadeh's Latest Holdings Summary section.
Transaction Summary of Behzad Aghazadeh
Behzad Aghazadeh Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Behzad Aghazadeh owns 4 companies in total, including CymaBay Therapeutics Inc (CBAY) , Immunomedics Inc (IMMU) , and Mirati Therapeutics Inc (MRTX) among others .
Click here to see the complete history of Behzad Aghazadeh’s form 4 insider trades.
Insider Ownership Summary of Behzad Aghazadeh
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| CBAY | CymaBay Therapeutics Inc | 2020-08-03 | 10 percent owner |
| IMMU | Immunomedics Inc | 2020-06-18 | director & 10 percent owner & other: See Remarks |
| MRTX | Mirati Therapeutics Inc | 2017-09-15 | 10 percent owner |
| AADI | Aadi Bioscience Inc | 2021-08-26 | director & other: See Remarks |
Behzad Aghazadeh Latest Holdings Summary
Behzad Aghazadeh currently owns a total of 1 stock. Behzad Aghazadeh owns 16,064,461 shares of Immunomedics Inc (IMMU) as of November 15, 2017, with a value of $1.4 Billion.
Latest Holdings of Behzad Aghazadeh
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| IMMU | Immunomedics Inc | 2017-11-15 | 16,064,461 | 87.86 | 1,411,423,543 |
Holding Weightings of Behzad Aghazadeh
Behzad Aghazadeh Form 4 Trading Tracker
According to the SEC Form 4 filings, Behzad Aghazadeh has made a total of 0 transactions in Immunomedics Inc (IMMU) over the past 5 years. The most-recent trade in Immunomedics Inc is the acquisition of 1,325,000 shares on November 15, 2017, which cost Behzad Aghazadeh around $14 Million.
Insider Trading History of Behzad Aghazadeh
- 1
Behzad Aghazadeh Trading Performance
GuruFocus tracks the stock performance after each of Behzad Aghazadeh's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Behzad Aghazadeh is 44.95%. GuruFocus also compares Behzad Aghazadeh's trading performance to market benchmark return within the same time period. The performance of stocks bought by Behzad Aghazadeh within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Behzad Aghazadeh's insider trading performs compared to the benchmark.
Performance of Behzad Aghazadeh
Average Relative Return
70.36%
Outperforming Transactions
100%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Relative Return(%) | 10.18 | 44.95 | 69.19 | 70.36 | 25.71 | |
| Relative Return to S&P 500(%) | 5.84 | 38.45 | 63.46 | 63.9 | 15.4 |
Behzad Aghazadeh Ownership Network
Ownership Network List of Behzad Aghazadeh
Ownership Network Relation of Behzad Aghazadeh
Behzad Aghazadeh Owned Company Details
What does CymaBay Therapeutics Inc do?
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
Who are the key executives at CymaBay Therapeutics Inc?
Behzad Aghazadeh is the 10 percent owner of CymaBay Therapeutics Inc. Other key executives at CymaBay Therapeutics Inc include Chief Financial Officer Harish Shantharam , Vice President & Finance Daniel Menold , and Chief Scientific Officer Charles Mcwherter .
CymaBay Therapeutics Inc (CBAY) Insider Trades Summary
Over the past 18 months, Behzad Aghazadeh made no insider transaction in CymaBay Therapeutics Inc (CBAY). Other recent insider transactions involving CymaBay Therapeutics Inc (CBAY) include a net sale of 108,739 shares made by Charles Mcwherter , a net sale of 73,000 shares made by Paul T Quinlan , and a net sale of 120,100 shares made by Dennis D Kim .
In summary, during the past 3 months, insiders sold 154,186 shares of CymaBay Therapeutics Inc (CBAY) in total and bought 0 shares, with a net sale of 154,186 shares. During the past 18 months, 322,784 shares of CymaBay Therapeutics Inc (CBAY) were sold and 51,301 shares were bought by its insiders, resulting in a net sale of 271,483 shares.
CymaBay Therapeutics Inc (CBAY)'s detailed insider trading history can be found in Insider Trading Tracker table.
CymaBay Therapeutics Inc Insider Transactions
Behzad Aghazadeh Mailing Address
Above is the net worth, insider trading, and ownership report for Behzad Aghazadeh. You might contact Behzad Aghazadeh via mailing address: C/o Avoro Capital Advisors Llc, 110 Greene Street, Suite 800, New York Ny 10012.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
